The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION PhRMA Chairman Says Budget Issues Controllable with Generics
June 4, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 1: 35 Listed Drug Makers See Downtrend in Profits Despite 3% Sales Uptick
June 4, 2015
-
ACADEMIA Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
-
REGULATORY MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
-
REGULATORY MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
-
REGULATORY AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
-
ORGANIZATION Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
May 29, 2015
-
REGULATORY MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
-
ORGANIZATION FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
May 28, 2015
-
REGULATORY MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
-
BUSINESS Astellas’s New 3-Year Plan Targets Sales Growth in Mid-Single-Digit Range
May 27, 2015
-
REGULATORY ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
-
BUSINESS Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement
May 26, 2015
-
BUSINESS Sales Increase 19.3% for 3 Generic-Only Makers; Incentive for DPC Hospitals Spurs Growth
May 25, 2015
-
TRENDS Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
BUSINESS Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit
May 21, 2015
-
REGULATORY Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
-
BUSINESS Top 4 Drug Wholesalers Report 0.82% Operating Profit Rate in FY2014
May 20, 2015
-
BUSINESS Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
-
REGULATORY Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…